Soligenix to advance synthetic hypericin development in psoriasis

Princeton, n.j., sept. 16, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that following the validation of synthetic hypericin's biologic activity in the positive pivotal phase 3 flash (fluorescent light activated synthetic hypericin) study in cutaneous t-cell lymphoma (ctcl), as well as positive proof-of-concept (poc) demonstrated in a small phase 1/2 pilot study in mild-to-moderate psoriasis patients, the company will be expanding this novel therapy under the research name sgx302 into psoriasis, a large and underserved market with a significant unmet medical need.
SNGX Ratings Summary
SNGX Quant Ranking